ArticleBMC geriatrics2025
Study of rheumatoid arthritis in older patients: a cross-sectional study.
Article in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Geroscience insights into difficult-to-treat rheumatoid arthritis: the role of unhealthy aging, comorbidity, and therapeutic complexity.GeroScience · 2026Review
- Geriatric nutritional risk index and mortality risk in elderly patients with rheumatoid arthritis: evidence from NHANES (1999-2018).Clinical rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatoid Arthritis (RA) in older adults is a chronic inflammatory condition causing severe disability and impacting patients' physical, psychological, and social health. It lowers productivity in society and puts pressure on healthcare systems. This study aims to explore the different aspects of RA and investigate the diagnostic potential of serum marker 14-3-3η.
methodThis Cross-sectional study recruited 205 arthritis patients (63 RA and 142 OA) over sixty years old. The participants underwent a thorough clinical evaluation according to the established design. Anti-CCP and serum 14-3-3η levels were measured. Simple logistic regression was performed to identify significant predictors of RA. ROC curve determined optimal cut-off value for 14-3-3η.
resultsThis study reported an average age of 63.67 years with a high female-to-male ratio of 4:1 in the RA cohort, while in the OA cohort, the mean age was 65.5 years with a low female-to-male ratio of 2:1 overall. Symptomatically, RA patients exhibited earlier onset, pronounced early morning stiffness, fever, weight loss, myalgia, and fatigue, all with highly significant p-values (< 0.001). Comorbidities showed higher incidences of anemia, ILD, and osteoporosis in RA patients. Impaired ADL and IADL were noted in 17.5% and 73.2%, respectively. Impaired HMSE and GDS were found in 36.5% and 74.6%, respectively. Logistic regression analysis identified key predictors distinguishing RA from OA, including EMS (OR: 1.09, p < 0.001), fever (OR: 6.68, p < 0.001), weight loss (OR: 6.35, p < 0.001), myalgia (OR: 5.07, p < 0.001), osteoporosis (OR: 2.21, p = 0.013), ACCP levels (OR: 1.28, p < 0.001), and the novel marker 14-3-3η (OR: 2.87, p = 0.047). Using both ACCP and14-3-3η markers, 88.88% of RA patients were positive for at least one marker, enhancing its diagnostic coverage. Elderly onset RA (EORA) patients had a significantly higher age and shorter disease duration compared to those with young onset RA (YORA). The female-to-male ratio in the YORA and EORA group were 6.97:1 and 1.66:1 respectively. PMR-like symptoms were more prevalent in the EORA group (31.25% vs.14.9%). Hypothyroidism was more frequent in the EORA group (31% vs. 17%). Sulfasalazine was more commonly prescribed in both EORA (100%) and YORA (89%) groups.
conclusionThis study contributes to a better understanding of distinguishing RA from OA. It also highlights the differences between young and elderly onset RA, and supports the diagnostic potential of the serum marker 14-3-3η.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.